[team_member image_url=”14695″ bio_alt_image_url=”14695″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Eric Soyer” job_position=”Chief Financial Officer” team_member_bio=”Eric joined MaaT Pharma in November 2024 as Chief Financial Officer.
Eric is a senior financial executive with extensive experience in the biotech industry with companies listed on Euronext Paris and on the U.S. Nasdaq market. Prior to joining MaaT Pharma, Eric successfully conducted as CFO & COO of Erytech Pharma, a French late-stage drug development company, its Nasdaq IPO and subsequent financial rounds amounting to over EUR 300 million and supervised the scale-up of the company’s operations from a single site based in France to a multi-site company of 240 employees in US and Europe and most recently its strategic merger. Throughout his 30-year career, Eric has developed a solid international experience across a variety of operational settings.” social_icon_1=”fa fa-linkedin” social_link_1=”https://www.linkedin.com/in/eric-soyer-2207506/”][/team_member]

[team_member image_url=”2650″ bio_alt_image_url=”2650″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Carole Schwintner” job_position=”Chief Technology Officer” team_member_bio=”Carole is the Chief Technology Officer at MaaT Pharma and has led MaaT Pharma’s pharmaceutical development activities since 2014. She brings 20 years of experience in the pharmaceutical industry, having previously held multiple responsibilities in cGMP manufacturing at Biorad and has been in charge of operations for a start-up company specializing in glycosylated proteins. She is the co-author of 7 published patents and 7 scientific publications.

PhD in microbiology, Engineer in Agronomy, Genetics and Biotechnology” social_icon_1=”fa fa-linkedin” social_link_1=”https://www.linkedin.com/in/carole-schwintner-43518033/”][/team_member]

[team_member image_url=”12865″ bio_alt_image_url=”12865″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” social_icon_1=”fa fa-linkedin” name=”Gianfranco Pittari” job_position=”Chief Medical Officer” team_member_bio=”Dr. Pittari brings over 15 years of international experience in clinical research and drug development in hematology, oncology, and immunology. He led successful Phase I-III clinical trials at Celgene Corporation – Bristol Myers Squibb, playing a key role in developing Abecma® (idecabtagene vicleucel), the first CAR T cell therapy for Multiple Myeloma (earlier lines of treatment) approved in the US and EU. Prior to joining MaaT Pharma, he was Executive Medical Director at Autolus and Senior Consultant Hematology-BMT at the National Center for Cancer Care and Research in Qatar.

M.D. degree from the University of Pavia, Hematology fellowship at the University of Parma, and Ph.D. in Immunology from Paris-Sud University.
Academic research at Gustave Roussy and Memorial Sloan-Kettering Cancer Center.” social_link_1=”https://www.linkedin.com/in/gianfrancopittari/”][/team_member]

[team_member image_url=”14802″ bio_alt_image_url=”12188″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” social_icon_1=”fa fa-linkedin” name=”Jonathan Chriqui” job_position=”Chief Business Officer” team_member_bio=”Jonathan brings over 15 years of business development experience working at Ipsen and Servier, including leadership in strategic transactions in the field of microbiota as well as collaborations, licensing, M&A, and alliance management. Previously, he held the role of Chief Operating & Chief Business Development Officer at Somagenetix in Zurich, Switzerland, which is developing gene therapies for rare diseases in immunology, neurology, and oncology.

PharmD” social_link_1=”https://www.linkedin.com/in/jonathanchriqui/”][/team_member]

[team_member image_url=”10289″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Karim Dabbagh” job_position=”Chairman of the Board – independent Director” team_member_bio=”Karim Dabbagh, PhD, is Chairman and independent Director since June 2023, succeeding Jean-Marie Lefevre who will continue to serve as a Board member.
Based in the U.S., Karim Dabbagh, president and CEO of Second Genome Inc., renowned for his innovative work in microbiome science and former executive at Pfizer and Roche, brings extensive experience in pharmaceutical development.

PhD in Biochemistry from University College, London
BSc (Hons) in Biotechnology from Imperial College, London” social_link_1=”https://www.linkedin.com/in/karimdabbagh/”][/team_member]

[team_member image_url=”15686″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Hervé Affagard” job_position=”CEO and co-founder” team_member_bio=”Hervé Affagard is the CEO and co-founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Hervé co-founded the company alongside Dr. Joël Doré, author of nearly 500 publications, and
one of the world’s most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Hervé has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA” social_icon_1=”fa fa-linkedin” social_link_1=”https://www.linkedin.com/in/haffagard/” social_icon_2=”fa fa-twitter” social_link_2=”https://twitter.com/HAffagard”][/team_member][divider line_type=”No Line” custom_height=”0″]

[team_member image_url=”2653″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Dr. Claude Bertrand” job_position=”Independent director” team_member_bio=”Claude joined MaaT Pharma as an Independent board member in July 2020. Since 2017, Claude has held the position of Executive Vice President of R&D and Chief Scientific Officer at Servier. He brings decades of high-level leadership in pharmaceutical R&D, having previously served as Executive Vice-President of R&D at Ipsen Pharma and as Global Senior Vice President for Respiratory & Inflammation Research Area at AstraZeneca. His career also includes senior positions at Novartis, Roche and Pfizer.

PharmD, PhD” social_icon_1=”fa fa-linkedin” social_link_1=”https://www.linkedin.com/in/claude-bertrand-374580/”][/team_member]

[team_member image_url=”5900″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Dorothée Burkel” job_position=”Independent director” team_member_bio=”Dorothée Burkel holds a Master’s degree from the Institut d’Etudes Politiques in Paris and is an independent director on the board of Directors. She is also Director of Human Resources, Information Systems and Communication and a member of the Executive Committee of PartnerRe. She brings decades of high-level experience in human resources and communication, having participated in the transformation of companies at an international level in the new technology and financial sectors.
She was formerly HR Director EMEA at Google and HR Director France at AOL.

Chief Corporate and People Operations Officer” social_icon_1=”fa fa-linkedin” social_link_1=”https://www.linkedin.com/in/doroth%C3%A9e-burkel-415620/”][/team_member]

[team_member image_url=”5898″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Jean Volatier” job_position=”Independent director” team_member_bio=”Jean Volatier is a graduate of the Magistère en Sciences de Gestion de l’Universtité Paris IX Dauphine (PSL), of the D.E.S.C.F. and of the Master en Executive Mangement Globale RSE de Mines Paris Tech (PSL) and is an independent director on the Board of Directors. Jean Volatier is currently CFO at Inventiva. Prior to that, he started his career at Pricewaterhouse Coopers in Paris and Philadelphia. He then moved to different positions in the Finance Department, first at Laboratoires URGO Soins & Santé and then internationally at Laboratoires Fournier, before holding different positions as CFO at the Soufflet and NAOS groups.

CFO” social_icon_1=”fa fa-linkedin” social_link_1=”https://www.linkedin.com/in/jean-volatier-49842311/”][/team_member][divider line_type=”No Line” custom_height=”0″]

[team_member image_url=”2662″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Isabelle de Crémoux” job_position=”Non-Executive Director” team_member_bio=”Isabelle de Crémoux is CEO and Managing Partner of Seventure Partners and leads the Life Sciences team. She joined Seventure in 2001 to establish the Life Sciences division. Isabelle supervises the Life Sciences business and personally invests in French and Scandinavian and north American biotech, nutrition, healthcare, personalized medicine. Isabelle has a particular interest in the microbiome field and frequently gives lectures at conferences in this domain. As a visionary, she launched Health for Life Capital™, the first European investment vehicule to support the microbiome revolution. Prior to joining Seventure Partners, she worke at Arthur Andersen/ EY, Pfizeer and Laboratoires Fournier.

Engineering degree from Ecole Centrale Paris” social_icon_1=”fa fa-linkedin” social_link_1=”https://www.linkedin.com/in/isabelle-de-cremoux-948214/”][/team_member]

[team_member image_url=”2802″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Jean-Marie Lefevre” job_position=”Chairman of the Board – Non-Executive Director” team_member_bio=”Jean-Marie has been President and CEO of Biocodex. He steered the creation of the “Biocodex Microbiota Institute” supporting innovative projects from Microbiota researchers. Jean-Marie has a long-track record of CEO positions amongst international firms such as LVMH or Bongrain.

Engineering degree Ecole Centrale Paris, MBA from Insead”][/team_member]

[team_member image_url=”6120″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Muriel Prudent” job_position=”Non-Executive Director” team_member_bio=”Muriel Prudent is an Investor at Bpifrance, French public investment bank, managing a portfolio of health- and other deeptech startups within the PSIM Fund, which focuses on major tech disruptions.
Graduated from HEC Paris and Bocconi University in Milan.” social_icon_1=”fa fa-linkedin” social_link_1=”https://www.linkedin.com/in/murielprudent/?locale=en_US”][/team_member]

[team_member image_url=”10287″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Nadia Kamal” job_position=”Independent director” team_member_bio=”Nadia Kamal, PhD, Director of the Technology, Health, and Innovation Divisions at Harmonie Mutuelle, has been appointed in June 2023 as independent director and Chair of the ESG committee. Nadia brings a wealth of experience in Corporate Social Responsibility and a strong background in serving patients and fostering innovation.

Doctorate in immuno-analysis and innovation in clinical biology – Sanofi Diagnostics Pasteur / CNRS.
Master’s degree in Business Administration from IAE Poitiers.
Artificial Intelligence in Health University Diploma at Université Paris Cité.” social_icon_1=”fa fa-linkedin” social_link_1=”https://www.linkedin.com/in/nadiakamallifesciences/”][/team_member]

[team_member image_url=”2656″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Dr. Ernst Holler” job_position=”MD, PhD” team_member_bio=”Dr. Ernst Holler was Director of the Clinical and Experimental Allogeneic Stem Cell Transplant Program in the Department of Internal Medicine at the University of Regensburg, Germany, for more than 20 years and is now Senior Professor on Translational Research in GvHD.

With more than 250 peer-reviewed manuscripts to his name, he is an expert in the field of Graft-vs-Host-Disease and was awarded the Van Bekkum Award, the highest award from the European Society for Stem Cell Transplantation.”][/team_member]

[team_member image_url=”8220″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Pr. Hassane Zarour” team_member_bio=”Professor of Medicine, Immunology and Dermatology at University of Pittsburgh School of Medicine, Pr. Zarour is a Cancer Immunologist with a long-lasting interest in cancer immunotherapies, cancer vaccines and human T cell immunology. His research focuses on immunotherapies of melanoma, T cell responses to melanoma antigens and on the mechanisms of melanoma-induced T cell dysfunction. He has made seminal contributions in the field of human cancer immunology, identifying multiple novel tumor antigen-specific CD4 epitopes, and determining the role of the novel inhibitory receptor pathways Tim-3 and TIGIT in impeding T cell responses to melanoma. Most recently, he has initiated translational studies evaluating the role of the gut microbiome in regulating clinical responses to PD-1 blockade in melanoma, including a first-in-human clinical trial to evaluate the safety and efficacy of fecal microbiota transplant (FMT) obtained from long-term PD-1 responder patients and pembrolizumab in PD-1 refractory melanoma patients. As a co-leader of the of the Cancer Immunology and Immunotherapy Program (CIIP), he will contribute to its mission, and together with basic and clinical investigators, foster the translation of novel laboratory findings into novel immunotherapy of cancers.

Co-Leader of the Melanoma and Skin Cancer SPORE
Co-Leader Cancer Immunology and Immunotherapy Program” job_position=”MD, PhD” social_icon_1=”fa fa-linkedin” social_link_1=”https://www.linkedin.com/in/hassanezarour/” social_icon_2=”fa fa-twitter” social_link_2=”https://twitter.com/hassanezarour”][/team_member]

[team_member image_url=”2675″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Dr. Robert Jenq” job_position=”MD” team_member_bio=”Robert R. Jenq, M.D., is director of the City of Hope® Microbiome Program and a clinical professor in the Department of Hematology and Hematopoietic Cell Transplantation. With more than 20 years’ experience as a physician-scholar with expertise in fields such as genomics, bone marrow and stem cell transplantation, Dr. Jenq is committed to bringing leading-edge translational research from the lab to cancer patients’ bedsides.”][/team_member]

[team_member image_url=”2657″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Dr. Florent Malard” team_member_bio=”Dr. Florent Malard is a hematologist at the Hospital Saint-Antoine and an Associate Professor at Sorbonne University in Paris, France. His research interests were clinical and translational studies on allogeneic hematopoietic stem cell transplantation, with a particular focus on preclinical studies on graft-versus-host disease. He joined Dr. van den Brink’s laboratory to study thymopoiesis reconstitution after thymic injury, particularly after allogeneic hematopoietic stem cell transplantation.
His research includes clinical and translational studies on allogeneic hematopoietic stem cell transplantation with a particular focus on preclinical studies on GvHD and has published over 100 peer-reviewed manuscripts.” job_position=”MD, PhD” social_icon_1=”fa fa-twitter” social_link_1=”https://twitter.com/Florent_Malard”][/team_member]

[team_member image_url=”2676″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Dr. Robert Zeiser” team_member_bio=”Prof. Dr. Robert Zeiser is Head of the Tumor Immunology and Immune Modulation at the Medical Center of the University of Freiburg in Germany. His research and treatment focus on acute leukemia, malignant melanoma, tumor cell migration, allogeneic hematopoietic stem cell transplantatio, and functional imaging. Professor Zeiser is the winner of the Artur Pappenheim Prize 2014 of the German Society for Hematology and Medical Oncology (DGHO) and the Richtenhain Prize 2016 of the German Cancer Research Center.” job_position=”Prof. Dr.”][/team_member]

[team_member image_url=”2686″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Dr. Jonathan Peled” job_position=”MD, PhD” team_member_bio=”Dr. Peled is a medical oncologist at the Memorial Sloan Kettering Cancer Center. Dr Peled specializes in bone marrow transplantation for blood cancers including leukemias, multiple myeloma, myelodysplastic syndrome, and lymphoma.

He studies how the intestinal microbiota interact with the host immune system as it relates to hematopoietic stem-cell transplantation, with a particular interest in graft-vs-tumor activity and graft-vs-host disease.

His long-term research goals include developing microbiota-based biomarkers that will be clinically useful in the care of transplant recipients, as well as microbiota-targeted therapeutic strategies to improve patient outcomes.” social_icon_1=”fa fa-linkedin” social_link_1=”https://www.linkedin.com/in/jonathan-peled-12817b65/”][/team_member]

[team_member image_url=”8218″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Pr. Franck Carbonnel” job_position=”MD, PhD” team_member_bio=”Franck Carbonnel, MD, PhD, is a professor of Gastroenterology at the Université Paris Saclay since 2008. and the head of the Gastroenterology Department at the University Hospital of Kremlin Bicêtre (Assistance Publique-Hôpitaux de Paris). He is specialized in inflammatory bowel disease care and research (clinical, epidemiological and translational). He is also involved in care of patients with enterocolitis due to immune-checkpoint inhibitors and contributed to their description. He recently investigated the role of intestinal microbiota to predict response and intestinal toxicity of immune checkpoint inhibitors.

MD, PhD” social_icon_1=”fa fa-linkedin” social_link_1=”https://www.linkedin.com/in/franck-carbonnel-4a606782/”][/team_member]

[team_member image_url=”8222″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Dr. Joël Doré” team_member_bio=”Joël is a worldwide renowned researcher with more than 200 publications relating to the Host/Microbiome interaction. Joël Doré is a research director in the Joint Research Unit for Food and Gut Microbiology for Human Health and scientific director of the MetaGenoPolis, both of which are part of INRA Île-de-France – Jouy-en-Josas and brings more than 30 years of research in the Microbiome field. Now one of the most cited scientists in the world (HiCiSci), he began his research on animals.

PhD” job_position=”Scientific Advisor” social_icon_1=”fa fa-linkedin” social_link_1=”https://www.linkedin.com/in/joel-dore-25aa1275/” social_icon_2=”fa fa-twitter” social_link_2=”https://twitter.com/dorejoel”][/team_member]

[team_member image_url=”2673″ team_memeber_style=”bio_fullscreen_alt” image_loading=”default” team_member_bio_full_html=”simple” name=”Pr. Mohamad Mohty” team_member_bio=”Doctor Mohamad Mohty is Professor of Haematology, and head of the Haematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). He also leads a translational research team (INSERM team) at the Saint-Antoine Research Center, Paris, France. He. Over the past 25 years or so, Professor Mohty, an active member of the EBMT, has always been a key figure of the EBMT and in the stem cell transplant and cellular therapy field. He has published over 600 peer-reviewed articles internationally and lectured in more than 70 countries.
In 2021, Professor Mohty has been nominated a “Chevalier de la Légion d’Honneur”, the highest French award, and one of the world’s most widely recognized decorations.

MD, PhD” job_position=”Medical Hematology – Oncology Advisor” social_icon_1=”fa fa-linkedin” social_link_1=”https://www.linkedin.com/in/mohamad-mohty-a573411bb/” social_icon_2=”fa fa-twitter” social_link_2=”https://twitter.com/Mohty_EBMT”][/team_member]